Prestige Consumer Prices Offering of $400 Million 6.25% Senior Notes Due 2034 >PBH
Prestige Consumer Healthcare Inc. (PBH) has priced an offering of $400 million in 6.25% senior notes due 2034. These notes will be issued at 100% of their face value. The offering is expected to close on July 10, 2026, subject to customary closing conditions.
Prestige Consumer Healthcare closes LaCorium acquisition for $150m
Prestige Consumer Healthcare Inc. has finalized its acquisition of LaCorium Health for approximately $150 million and also priced a $400 million senior notes offering. The acquisition of the Australian therapeutic skin care business, generating $40 million in annual revenue, is expected to add $12 million in EBITDA. The company plans to use the proceeds from the senior notes offering to redeem existing 5.125% Senior Notes due 2028.
Prestige Consumer Healthcare Completes LaCorium Acquisition and Prices $400 Million Notes Offering
Prestige Consumer Healthcare Inc. (NYSE: PBH) has finalized its acquisition of Australian skincare company LaCorium Health for approximately $150 million. Concurrently, Prestige priced a $400 million offering of 6.25% senior notes due 2034 to refinance existing debt. The company also announced it would release its fiscal 2027 first-quarter financial results on August 6th.
Prestige Brands, Inc. Amends Term Loan Credit Agreement and Announces Private Offering of $400 Million Senior Notes
Prestige Consumer Healthcare Inc. amended its Term Loan Credit Agreement to borrow an additional $95.0 million to finance the acquisition of LaCorium Health Australia Pty Limited and its related entities. Concurrently, the company announced a private offering of $400 million senior unsecured notes due 2034. The proceeds from this offering, along with cash on hand, will be used to redeem Prestige Brands' outstanding 5.125% Senior Notes due 2028.
Prestige Consumer (NYSE: PBH) closes LaCorium deal, prices $400M notes
Prestige Consumer Healthcare Inc. (NYSE: PBH) has successfully completed its acquisition of Australian skincare company LaCorium Health for approximately $150 million. The company also priced a private offering of $400 million in 6.25% senior unsecured notes due 2034, which will be used along with cash on hand to redeem existing 5.125% Senior Notes due January 2028. LaCorium is expected to add $40 million in annual revenue and about $12 million in EBITDA to Prestige Consumer Healthcare's financials.
Prestige Consumer Healthcare Secures $95 Million Term Loan Amendment for LaCorium Acquisition
Prestige Consumer Healthcare (PBH) secured a $95 million term loan amendment to finance its acquisition of LaCorium, covering associated fees. The amendment was executed and became effective on July 1, 2026, with the company's subsidiary borrowing the full amount upon closing. Citibank acted as the administrative agent for the lenders.
Prestige Consumer buys LaCorium, then prices $400M debt deal
Prestige Consumer Healthcare Inc. completed its acquisition of LaCorium Health for approximately $150 million and priced a private offering of $400 million in 6.25% senior notes due 2034. The company intends to use the proceeds from the debt offering, along with cash on hand, to redeem its outstanding 5.125% senior notes due January 2028. Additionally, Prestige Consumer Healthcare will release its first-quarter fiscal 2027 earnings on August 6, 2026, followed by a conference call.
Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date
Prestige Consumer Healthcare Inc. has announced the completion of its acquisition of LaCorium Health for approximately $150 million, financed with cash on hand and existing credit facilities. The company also priced a private offering of $400 million in 6.25% senior notes due 2034, with proceeds intended to redeem outstanding 5.125% Senior Notes due January 2028. Additionally, Prestige Consumer Healthcare will release its first-quarter fiscal 2027 earnings on August 6, 2026.
Prestige Consumer Healthcare Inc. (PBH): A Top Ariel Investments Stock to Buy Following Breathe Right Brand Acquisition
Prestige Consumer Healthcare Inc. (NYSE: PBH) is highlighted as a top stock by Ariel Investments following its recent acquisition of the Breathe Right brand and other brands from Foundation Consumer Healthcare for $1.045 billion. This acquisition is expected to significantly enhance Prestige Consumer Healthcare's portfolio, making Breathe Right its largest brand with substantial revenue and profit in 2025. The move reinforces the company's position as a leading independent provider of over-the-counter healthcare products in North America.
Prestige Consumer Healthcare unit plans $400M notes offering
Prestige Consumer Healthcare Inc. announced that its subsidiary, Prestige Brands, Inc., plans to offer $400 million in senior unsecured notes. The proceeds from this offering will be used to repurchase outstanding 5.375% senior notes due in 2026 and to pay related fees and expenses.
Prestige Plans $400 Million Private Offering of Senior Notes
Prestige Brands Holdings, Inc. announced a private offering of $400 million in senior notes due 2024 to eligible purchasers. The company plans to use the net proceeds from this offering, along with borrowings under its revolving credit facility, to redeem all of its outstanding 8.250% Senior Notes due 2021. This strategic move aims to refinance existing debt and optimize its capital structure.
Prestige Consumer Healthcare Inc. Announces Offering Of $400 Million Senior Notes
Prestige Consumer Healthcare Inc. has announced an offering of $400 million in senior notes. This brief report, sourced from Reuters and Refinitiv, indicates a financial move by the company. Further details are not provided in this short news piece.
Prestige Consumer Healthcare Announces Proposed Private Offering of $400 Million Senior Notes Due 2034 to Redeem 2028 Notes
Prestige Consumer Healthcare Inc. is planning a private offering of $400 million in senior notes due 2034 through its subsidiary, Prestige Brands, to qualified institutional buyers. The proceeds from this offering will be used to redeem all outstanding 5.125% Senior Notes due 2028, aiming to optimize the company's debt structure and reduce interest expenses. The redemption is conditional on the successful completion of the new financing, though this condition can be waived.
Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes
Prestige Consumer Healthcare Inc. announced an offering of up to $400 million in aggregate principal amount of new senior notes due 2034 by its wholly-owned subsidiary, Prestige Brands, Inc. The company intends to use the net proceeds, along with cash on hand, to redeem its outstanding 5.125% Senior Notes due 2028. The offering is private, targeting qualified institutional buyers and persons outside the U.S.
Prestige Consumer lines up $400M debt refinancing due 2034
Prestige Consumer Healthcare (NYSE: PBH) through its subsidiary Prestige Brands, plans a private offering of up to $400 million in senior unsecured notes due 2034. The net proceeds, along with cash on hand, will be used to redeem all of Prestige Brands' existing $400 million 5.125% senior notes due 2028 and cover associated fees. The redemption of the 2028 notes is contingent upon the successful completion of the new notes offering of at least $400 million.
Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes
Prestige Consumer Healthcare Inc. announced that its subsidiary, Prestige Brands, Inc., plans to offer $400 million in senior notes due 2034. The net proceeds, along with cash on hand, will be used to redeem all outstanding 5.125% Senior Notes due 2028. This offering is subject to market and other conditions and is being made in a private offering to qualified institutional buyers.
[8-K/A] Prestige Consumer Healthcare Inc. Amends Material Event Report
Prestige Consumer Healthcare Inc. (PBH) has filed an amended 8-K report to provide comprehensive historical and unaudited pro forma financial statements for its $1,045.0 million acquisition of the OTC Wellness Business, including Breathe Right, from Foundation Consumer Brands. The acquisition, funded by a new Term Loan Credit Agreement, significantly impacts Prestige's financials, showing pro forma combined net sales of $1,284.8 million and net income of $180.6 million for the twelve months ending March 31, 2026. This filing details the allocation of the purchase price to intangible assets and goodwill and outlines the associated debt structure and interest expenses.
Prestige Consumer Healthcare Inc. ($PBH) Chair, President, and CEO 2026 Pay Revealed
Prestige Consumer Healthcare Inc.'s CEO, Ronald M. Lombardi, is estimated to have received $6,004,547 in compensation in 2026, a 3.14% decrease from 2025. This compensation information is based on a new DEF14A SEC filing. The article also details insider trading activities, hedge fund movements, and recent analyst price targets for PBH stock.
Prestige Consumer Healthcare Inc.(NYSE:PBH) dropped from Russell 3000E Growth Benchmark
Prestige Consumer Healthcare Inc. (NYSE: PBH) has been removed from the Russell 3000E Growth Benchmark. This news follows a series of recent events for the company, including the acquisition of Breathe Right, new product announcements for Dramamine, and soft Q4 2026 earnings results which led to an analyst downgrade.
Prestige Consumer Healthcare Inc Actuals & Estimates (NYSE:PBH)
This article provides an overview of Prestige Consumer Healthcare Inc. (NYSE: PBH) stock, including current and historical prices, market capitalization, analyst forecasts, and financial data. It highlights the stock's recent performance, earnings, revenue, and upcoming earnings report. The piece also addresses frequently asked questions about the company's financials and investment potential.
PBH Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Prestige Consumer Healthcare Inc. (PBH) stock for 2027, based on analyst opinions. It includes current stock performance, market capitalization, earnings data, and key financial metrics, alongside an overview of analysts' recommendations. The piece also addresses frequently asked questions about PBH stock, such as its volatility, dividend policy, and how to trade it.
Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, Hagens Berman Investigating
Hagens Berman is investigating Prestige Consumer Healthcare (PBH) after the company's stock fell over 11% due to significant revenue declines and production problems, particularly with its Clear Eyes® brand and the recently acquired Pillar5 facility. The investigation focuses on whether Prestige was transparent about its ability to resolve supply chain constraints before its Q4 2026 results were announced. Investors who suffered losses are encouraged to contact the firm.
Prestige Consumer Healthcare Inc
This article provides a revenue breakdown for Prestige Consumer Healthcare Inc (PBH), detailing its regional revenue contributions. Specifically, it highlights that 78.89% of its revenue comes from the United States, totaling $897.54 million, with the rest of the world contributing 21.11% or $240.22 million. The report indicates that business segment data for recent fiscal years is not yet disclosed by the company.
Prestige Consumer Healthcare Inc (PBH) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Prestige Consumer Healthcare Inc (PBH), highlighting its current earnings forecast score of 8.00 and an average price target of $76.00 among analysts. It details the upside potential, analyst ratings (predominantly "Buy"), and expected revenue and EPS for upcoming periods. Key financial forecasts suggest an expected revenue of $249.68M and an EPS of $0.88 for the next quarter.
Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®
Prestige Consumer Healthcare Inc. announced the completion of its acquisition of the Breathe Right® brand and other associated brands from Foundation Consumer Healthcare for $1.045 billion. This strategic move adds Breathe Right®, an iconic nasal strip brand, as Prestige's largest brand, expanding its product portfolio. The transaction was funded through available cash and a new Term Loan B.
Prestige closes $1 billion Breathe Right acquisition
Prestige Consumer Healthcare has completed its $1.045 billion acquisition of the Breathe Right brand, financed through cash and debt. This acquisition, which had a net cost of approximately $900 million after tax benefits, expands Prestige's product portfolio. Breathe Right, originally created in the 1990s, is expected to become Prestige's largest product line.
Prestige Consumer Healthcare (PBH) Stock Could Be 30.1% Undervalued After Weak Earnings And Guidance
Prestige Consumer Healthcare (PBH) stock is reportedly 30.1% undervalued following recent weak earnings and cautious guidance, which led to a significant share price drop. Despite setbacks like Clear Eyes supply constraints and reliance on mature OTC brands, the company's strong free cash flow supports future EPS growth. The article suggests investors review independent data and explore other investment opportunities using focused screeners.
Prestige Consumer (NYSE: PBH) uses $1.045B term loan to buy Breathe Right
Prestige Consumer Healthcare Inc. (NYSE: PBH) has completed the acquisition of the Breathe Right business and other brands for $1.045 billion in cash, financed primarily through a new $1.045 billion Term Loan Credit Agreement. The deal, valued at approximately $900 million net of anticipated tax benefits, establishes Breathe Right as the company's largest brand, expanding its product portfolio. The company also secured additional liquidity, including a potential $95 million uncommitted term loan draw and an amended ABL Credit Facility, to potentially fund the planned LaCorium Health acquisition.
Prestige Consumer Healthcare Secures $1.045 Billion Term Loan, Expands ABL to $225 Million
Prestige Consumer Healthcare (PBH) has secured a $1.045 billion secured term loan to finance its acquisition of the Breathe Right business, with an option for an additional $95 million for the planned LaCorium Health acquisition. The company also amended its Asset-Based Lending (ABL) Credit Agreement, increasing commitments to $225 million and extending the facility for five years. Citibank is serving as the administrative agent for both financial agreements.
Prestige Consumer Healthcare Inc. Completes Acquisition of Breathe Right
Prestige Consumer Healthcare Inc. has completed the acquisition of the Breathe Right brand and other associated brands from Foundation Consumer Healthcare. This $1.0 billion acquisition, net of anticipated tax benefits, makes Breathe Right the largest brand for Prestige, expanding its presence into a new category. The transaction was financed through available cash and a new Term Loan B.
Prestige Consumer Healthcare completes $1.045 billion acquisition
Prestige Consumer Healthcare Inc. has completed its acquisition of the Breathe Right brand and other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated tax benefits. This acquisition, representing almost half of the company's market capitalization, expands Prestige into the nasal strip category, making Breathe Right its largest brand. Despite recent challenging Q4 earnings and an analyst price target reduction, InvestingPro analysis indicates that Prestige's stock may still be undervalued.
Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®
Prestige Consumer Healthcare Inc. (PBH) has completed its acquisition of the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated tax benefits. Breathe Right® is described as an iconic #1 nasal strip brand and will become Prestige's largest brand, expanding the company into a new category. The transaction was financed through available cash and a new Term Loan B.
Breathe Right nasal strips sold to Prestige in $1.045B deal
Prestige Consumer Healthcare (NYSE: PBH) has completed its $1.045 billion acquisition of the Breathe Right brand and other brands from Foundation Consumer Healthcare. This deal, valued at approximately $900 million net after tax benefits, makes Breathe Right Prestige's largest brand and expands its presence into the nasal strip product category. The acquisition was funded through available cash and new Term Loan B financing.
Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®
Prestige Consumer Healthcare Inc. (NYSE:PBH) has completed its previously announced acquisition of the Breathe Right® brand and other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of tax benefits. This acquisition establishes Breathe Right® as Prestige's largest brand, expanding its presence into the nasal strip category and was financed through existing cash and a new Term Loan B. Prestige Consumer Healthcare markets a diverse portfolio of consumer health products across the U.S., Canada, Australia, and other international markets.
PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Prestige Consumer Healthcare Inc. (NYSE: PBH) on behalf of investors. This investigation follows a significant drop in Prestige's stock price after the company reported a 4.5% organic revenue decrease and flat gross margins for fiscal year 2026. Investors who suffered losses are encouraged to contact the firm to discuss their rights.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
Pomerantz LLP is investigating potential securities fraud claims against Prestige Consumer Healthcare Inc. (NYSE: PBH) following a significant drop in its stock price. The investigation concerns whether the company's officers or directors engaged in unlawful business practices after Prestige reported a decrease in fiscal year 2026 revenues and disclosed that "Clear Eyes" sales were below expectations due to delayed shipments and production shutdowns. Investors are encouraged to contact Pomerantz LLP to learn more about the investigation.
Capital Research Global Investors Boosts Holdings in Prestige Consumer Healthcare Inc. $PBH
Capital Research Global Investors significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by 107.9% in the fourth quarter, now owning 561,497 shares valued at $34.6 million. Overall, institutional investors hold 99.95% of the company's stock. Despite this increased institutional interest, Prestige Consumer Healthcare recently missed earnings and revenue estimates, and analysts maintain a consensus "Hold" rating with a target price of $70.75 against its current trading price of $48.64.
Prestige Consumer Healthcare Inc. $PBH Position Raised by Brandes Investment Partners LP
Brandes Investment Partners LP significantly increased its stake in Prestige Consumer Healthcare Inc. by 93.2% in the fourth quarter, now owning 606,737 shares worth approximately $37.4 million. This increase occurred despite the company missing Wall Street's Q1 earnings and revenue estimates and a general softening of analyst sentiment, leading to a consensus "Hold" rating. Institutional investors collectively own a substantial 99.95% of the company's stock.
PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Prestige Consumer Healthcare Inc. (PBH) on behalf of investors alleging securities law violations. This follows a significant drop in Prestige's stock price after the company reported a 4.5% decrease in organic revenues for fiscal year 2026. Shareholders who suffered losses are encouraged to contact the firm to discuss their rights.
PBH: Major acquisitions and disciplined strategy position for strong growth and international expansion
Prestige Consumer Healthcare Inc. (PBH) is poised for strong growth and international expansion, driven by a disciplined strategy focusing on brand leadership, stable growth, and capital allocation. Recent major acquisitions, including Breathe Right and LaCorium Health, are expected to fuel above-average growth. The company is also benefiting from consumer shifts towards mass and e-commerce, along with operational improvements.
Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
Prestige Consumer Healthcare Inc. will participate virtually in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference on Monday, June 8, 2026, at 9:45 a.m. ET. A live webcast and replay will be available on the company's investor relations website. The company markets and distributes a diverse portfolio of consumer healthcare products internationally.
Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
Prestige Consumer Healthcare Inc. (NYSE: PBH) announced it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday, June 8, 2026, at 9:45 a.m. ET. A live webcast and replay of the event will be available on the company’s investor relations website. Prestige Consumer Healthcare markets and distributes a diverse portfolio of consumer healthcare products across the U.S., Canada, Australia, and other international markets.
Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
Prestige Consumer Healthcare Inc. (NYSE:PBH) has announced its virtual participation in the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference on Monday, June 8, 2026, at 9:45 a.m. ET. A live webcast and replay of the fireside chat will be available on the company's investor relations website. The company markets and distributes a diverse portfolio of consumer healthcare products internationally.
Prestige Consumer Healthcare Inc. (PBH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Prestige Consumer Healthcare Inc. (NYSE:PBH) following a significant 11.35% drop in stock price on May 14, 2026. This decline occurred after the company reported a revenue decrease for fiscal year 2026 and revealed that "Clear Eyes" sales were below expectations due to delayed shipments and production shutdowns. The firm encourages investors who purchased Prestige securities to contact them to learn more about the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Prestige Consumer Healthcare Inc. (PBH) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Prestige Consumer Healthcare Inc. (PBH) following a significant drop in its stock price. This decline occurred after Prestige announced lower-than-expected fourth-quarter and full-year 2026 earnings, including a 4.5% organic revenue decrease and flat gross margins, exacerbated by delayed shipments and production shutdowns for Clear Eyes. The firm is encouraging investors who purchased Prestige securities to join their investigation to potentially recover losses.
Why Canaccord Reduced Prestige Consumer Healthcare Inc. (PBH) Price Target After Q4 Weakness
Canaccord Genuity reduced its price target for Prestige Consumer Healthcare Inc. (PBH) from $86 to $72, while maintaining a Buy rating, following weaker-than-expected Q4 results attributed to softness in eye care and impacts from the Iran conflict. Despite this, Prestige Consumer Healthcare separately announced its acquisition of LaCorium Health for $150 million, a strategic move expected to bolster its portfolio with approximately $40 million in revenue and contribute $12 million in EBITDA after synergies. This acquisition aims to support the company's long-term growth and profitability within the consumer healthcare sector.
Bronstein, Gewirtz & Grossman, LLC Encourages Prestige Consumer Healthcare Inc. (PBH) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Prestige Consumer Healthcare Inc. (PBH) after the company announced lower-than-expected Q4 and full-year fiscal 2026 earnings, citing decreased revenues and production issues. Following this news, Prestige's stock price dropped significantly. The law firm is encouraging PBH stockholders to inquire about the securities investigation and potentially join a class action lawsuit.
11 Most Undervalued Pharma Stocks to Invest In
The article identifies Prestige Consumer Healthcare Inc. (NYSE: PBH) as one of the most undervalued pharma stocks, despite a recent price target cut by Canaccord Genuity due to weaker Q4 results and geopolitical events. Prestige Consumer Healthcare is acquiring LaCorium Health for $150 million, a move expected to strengthen its portfolio and contribute to long-term growth. The article also mentions a strategic shift towards AI stocks for higher returns and lists several other major pharmaceutical companies.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Prestige Consumer Healthcare Inc. (PBH) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Prestige Consumer Healthcare Inc. (NYSE:PBH) following its Q4 and full-year 2026 earnings report, which revealed a 4.5% organic revenue decrease and unmet Clear Eyes sales expectations due to production issues. Following this news, Prestige's stock price dropped over 11%. The firm encourages affected investors to learn more about the investigation and potentially participate in a class action lawsuit.
Prestige Consumer Healthcare Inc. (PBH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Prestige Consumer Healthcare Inc. (PBH) following a significant drop in its stock price. The investigation stems from Prestige's Q4 and full-year 2026 earnings announcement, which revealed a 4.5% organic revenue decrease and production shutdowns impacting Clear Eyes sales, leading to an 11.35% stock price decline. The firm encourages shareholders who purchased Prestige securities to contact them to assist with the investigation, which is conducted on a contingency fee basis.
